# Targeted Radionuclide Detection of Malignant Tumors Using Affibody

## TL;DR

This paper reviews how affibody molecules can be used to detect malignant tumors using radionuclides, showing promise in clinical applications.

## Contribution

The paper highlights the novel use of affibody conjugates with radioisotopes for targeted tumor imaging in clinical settings.

## Key findings

- Affibody molecules show high affinity and specificity for molecular targets in tumor visualization.
- Radiopharmaceuticals based on affibody conjugates are well-tolerated and effective in assessing tumor prevalence.
- Clinical trials support the use of affibody-based imaging for determining HER2/neu status in breast cancer patients.

## Abstract

This review examines the potential applications of affibody molecules in
various fields of biotechnology and clinical medicine. Consideration is given
to the high affinity and specificity of affibody molecules for selected
molecular targets, as well as their potential for the in vivo visualization of
various malignant tumors. Significant attention is paid to preclinical and
clinical studies of affibody conjugates with various radioisotopes for targeted
radionuclide tumor imaging, which is particularly relevant in addressing
challenges encountered during the diagnosis and treatment of these patients.
Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and
effective for the assessment of tumor process prevalence and the determination
of HER2/neu status in breast cancer patients, supporting further research.